which is related to MCP-1-induced angiogenesis. 15 Given the proinflammatory role of MCP-1, MCPIP may be involved in endothelial inflammatory responses.
The pleiotropic effect of statins involves its anti-inflammatory effect on the vasculature. 16 Under increased inflammation and oxidative stress, statins can restore eNOS-derived NO bioavailability. 17, 18 Simvastatin, atorvastatin, and lovastatin can inhibit the transactivation of nuclear factor-κB (NF-κB) in endothelial cells (ECs). 19 The Trial of Atorvastatin in Rheumatoid Arthritis study showed that statin reduces inflammation and clinical outcomes in patients with RA. 20 Assessing flow-mediated dilation of the brachial artery, Mäki-Petäjä et al 21 showed that both simvastatin and ezetimibe can restore the impaired endothelial function in RA patients. The beneficial effect of simvastatin on endothelial function in patients with RA is also supported by a trial conducted by Hermann et al. 22 In this study, we explored the pathogenic link between RA and endothelial dysfunction, with an emphasis on the role of MCPIP. Induction of MCPIP in the endothelium with sera from mice with collagen-induced arthritis (CIA) or patients with RA played a major role in RA-associated endothelial dysfunction. Furthermore, treatment with statins could alleviate NF-κB transactivation on MCPIP.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Endothelial Dysfunction in CIA Mice
In all mice receiving type II collagen, ≥1 paw ankle or wrist joint exhibited swelling 8 weeks after injection ( Figure 1A) .
Severe redness and swelling of the entire paw were found for most mice, and the joint clinical score was 9.8±1.5. Histological sections from proximal interphalangeal and metacarpophalangeal joints of the CIA models showed an increase in synovial proliferation and pannus but decrease in articular cavity, together with bone and cartilage inflammation and destruction ( Figure 1A) . The mean pathological score for joints with lesions was 6.2±2.0. However, CIA and control mice had similar body weight, blood glucose, and serum levels of total cholesterol and triglyceride ( Table III in the onlineonly Data Supplement) .
We examined whether endothelial function was affected by CIA-associated inflammation by examining vasorelaxation in mice. Vascular dilation was lower with Ach (endothelial-dependent) in CIA than control mouse aortas ( Figure 1B ). However, sodium nitroprusside-induced relaxation (endothelial-independent) was comparable between the 2 groups of mice. CIA mice were divided into moderate and low vascular dilation response groups by maximum relaxation percentage (66±11% and 42±7%); the score for the control group was 87±16%. Phosphorylation of eNOS Ser-1177 in pooled aortic extracts was lower for CIA than control mice. Those dilated poorer had lower level of eNOS phosphorylation ( Figure 1C ).
To examine whether CIA-associated inflammation affected eNOS-derived NO bioavailability in the endothelium through circulation, we incubated EOMA cells with sera pooled from CIA or control mice with or without vascular endothelial growth factor (VEGF). VEGF with control sera greatly induced eNOS phosphorylation in EOMA cells ( Figure 1D ), which was dose-dependently decreased with CIA sera. Endothelial dysfunction is present in collagen-induced arthritis (CIA). Arthritis was induced by collagen injection in DBA/1j mice as described in Methods. A, Top, Swelling in multiple joints and palms of CIA mice; bottom, histological features of increased synovial proliferation and inflammation in the interphalangeal joints of CIA mice. AC indicates articular cavity; AS, articular surface; B, bone; BD, bone destruction; CD, cartilage destruction; I, inflammation; C, cartilage; P, pannus; S, synovium; and SP, synovial proliferation (magnification, ×100). B, Aortic rings from CIA and DBA/1j control mice (4 per mouse) were treated with Ach or SNP for endothelium-dependent and endothelium-independent vaso-relaxation assays, respectively. Relaxation%=(millinewton at Phemillinewton at a certain concentration Ach or SNP)/ (millinewton at Phe-millinewton at balance)×100%. C, Aortic extracts were pooled from control (n=16) and CIA (n=8 each group) mice. D, EOMA cells were incubated with sera pooled from control or CIA mice (n=16) at the indicated concentrations for 24 hours, then stimulated with vascular endothelial growth factor (VEGF; 30 ng/mL) or an equal volume of medium for an additional 1 hour before lysis. Western blot analysis in C and D with anti-phospho-eNOS, anti-eNOS, and anti-GAPDH antibodies. Data in D are mean±SD from 3 independent cell experiments with the same pools of sera. *P<0.05 as compared with the respective control group. eNOS indicates endothelial NO synthase. June 2013
Elevated Serum Level of MCP-1 Inversely Correlates With Vessel Tone
Because CIA sera decreased eNOS phosphorylation in ECs, we then explored the factor(s) in the sera that might cause impaired eNOS phosphorylation. The levels of C5a, soluble intercellular adhesion molecule-1, MCP-1, tissue inhibitor of metaloproteinase 1, and monokine induced by gamma interferon in sera from the 2 groups of mice significantly differed on mouse cytokine array ( Figure 2A ). ELISA revealed levels of MCP-1, tissue inhibitor of metaloproteinase 1, and monokine induced by gamma interferon higher but C5a level lower in CIA than control sera ( Figure 2B ). We correlated concentrations of these cytokines with maximum vessel relaxation percentage induced by Ach in CIA mice and found only serum level of MCP-1 is inversely correlated (r=−0.517; P=0.04; Figure 2C ). To link results from CIA mice with clinical settings, sera from patients with OA or RA were incubated with cultured HUVECs. Likewise, RA sera reduced eNOS phosphorylation responding to VEGF, as compared with osteoarthritis sera ( Figure 2D ). Of note, the higher the concentration of serum MCP-1, the lower the eNOS phosphorylation. We further performed a complimentary experiment with aortic rings from normal DBA/1j mice treated with recombinant mouse MCP-1 from 1 to 3 ng/mL before assessing vaso-relaxation.
MCP-1 dose-dependently inhibited the Ach-induced vasorelaxation (Figure I in the online-only Data Supplement).
MCP-1 Induces MCPIP Expression in ECs
Although MCP-1 is known to decrease eNOS-derived NO bioavailability, 23 the exact molecular mechanism is still unknown. We speculated that MCPIP is involved in the endothelial dysfunction and thus compared the level of MCPIP in EOMA cells treated with CIA or control sera. CIA sera dose-dependently induced the expression of MCPIP in EOMA cells, which was blocked by antagonism of CCR2, the MCP-1 receptor ( Figure 3A ). Similar results were obtained with HUVECs treated with sera from RA patients ( Figure 3B ). In line with results in Figure 3A , MCPIP and CCR2 were highly expressed in aortas of CIA mice ( Figure 3C ), and high mRNA levels of MCP-1 were found in the ankle and aorta but not in liver of CIA mice ( Figure 
Elevated Level of MCPIP Decreases the eNOS-Derived NO Bioavailability
Given the commonly found MCPIP elevation in CIA serastimulated, RA sera-stimulated, and MCP-1-stimulated ECs, we then examined the role of MCPIP in eNOS-derived NO bioavailability. Knocking down MCPIP in EOMA cells with small interfering RNA restored the VEGF-induced phosphorylation of Akt and eNOS, as well as NO production ( Figure 4A and 4B). In vivo, administration of anti-MCP-1 antibody to CIA mice decreased the level of MCPIP but increased eNOS phosphorylation in the aorta ( Figure 4C ). The restoration of eNOS-derived NO bioavailability in these vessels was shown by increased endothelial-dependent dilation response to Ach ( Figure 4D ). We used a gain-of-function approach with MCPIP overexpression in HUVECs to test whether elevated MCPIP can impair NO bioavailability. VEGF-induced Akt and eNOS phosphorylation was hindered in HUVECs overexpressing exogenous MCPIP as compared with mock transfection controls ( Figure 5A ). Elevated MCPIP in cardiomyocytes is linked to increased oxidative stress. 13 We found that MCPIP overexpression increased oxidative stress in ECs, which was attenuated by coincubation with a permeable superoxide dismutase ( Figure 5B) . Similarly, CIA and RA sera decreased Akt and eNOS phosphorylation with attendant increased oxidative stress in EOMA cells and HUVECs, respectively ( Figure 5C-5F ). SOD treatment of these cells alleviated the imposed oxidative stress and partially restored the impaired Akt and eNOS phosphorylation ( Figure 5A, 5C, and 5E ).
Therefore, elevated MCPIP with increased oxidative stress contributes to impaired vascular tone during RA.
Statins Downregulate MCPIP Expression
Clinically, administration of statins can improve endothelial function in RA patients and reduce circulatory MCP-1 level in patients with coronary heart disease. 21, 22, 24 Consistently, we found that simvastatin administration to CIA mice for 9 weeks improved the vaso-relaxation response to Ach but not SNP ( Figure 6A and 6B ). In addition, the level of MCPIP was lower but phosphorylation of eNOS was higher in aortas of CIA mice receiving simvastatin than vehicle ( Figure 6C ). Treating EOMA cells with simvastatin or atorvastatin dose-dependently decreased the MCP-1-induced MCPIP protein and mRNA levels ( Figure 6D ; Figures III and IV in the online-only Data Supplement). Given that 4 putative NF-κB binding sites are present in the enhancer region of MCPIP, 25 we performed chromatin immunoprecipitation assay and found that MCP-1 stimulation of HUVECs increased the binding of the p65 subunit of NF-κB to the enhancer of the MCPIP (Figure 6E ). However, MCP-1 stimulation with simvastatin decreased the binding of NF-κB to the MCPIP gene enhancer, so the anti-inflammatory effect of statins was mediated at least in part by decreased NF-κB transactivation of MCPIP.
Discussion
Experiments involving CIA mice, as well as RA patient sera, revealed that MCP-1 induction of MCPIP plays a key role in endothelial dysfunction associated with RA. Elevated MCP-1 in circulation, directly or indirectly from ankle inflammation, increased the MCPIP level in the vascular endothelium. The consequent increased oxidative stress caused impaired eNOS-derived NO bioavailability (summarized in Figure 6F ). Because dysfunctional endothelium initiates many vascular diseases, 26 we suggest that MCPIP may link RA with impaired vascular functions. Exhibiting high and low inflammation, RA and atherosclerosis share a similar expression profile of cytokines and chemokines. 4 The proinflammatory cytokines highly expressed in inflammatory joints may have caused dysfunctional endothelium through endocrine actions. Although our data suggest that MCP-1 in both rodent and human RA plays a key role in inducing MCPIP level in endothelium, other RA-associated inflammatory cytokines, such as C-reactive protein or IL-1β, may also be involved. 12 Such a possibility is supported by previous studies showing MCPIP level upregulated by MCP-1 or IL-1β in monocytes, macrophages, HEK293 and HpeG2 cells, cardiomyocytes, and ECs. 10, [12] [13] [14] 25 Indeed, the level of C-reactive protein was positively correlated with that of MCP-1 in patient samples involved in the current study ( Figure V in the online-only Data Supplement). Elicited by multiple proinflammatory cytokines via NF-κB, MCPIP may thus be a common inflammatory mediator leading to impaired eNOS-derived NO bioavailability.
With respect to the molecular mechanism by which MCPIP exacerbates endothelial dysfunction, MCPIP-increased oxidative stress may negatively regulate eNOS phosphorylation, as seen in Figure 5 . In ECs, the major source of free radicals are NADPH oxidases, complex III of the mitochondrial respiratory chain, and reactive nitrogen species. 27 MCPIP overexpression in H9c2 cardiomyoblasts induced both reactive oxygen species and reactive nitrogen species production by upregulating NADPH oxidase subunit phox47 and inducible NOS. 14 Thus, the increased redox stress in ECs with elevated MCPIP level may be, in part, because of induction of phox47 and inducible NOS. With the structural feature of a transcription factor, 10 MCPIP may transcriptionally activate these freeradical-producing proteins. Regarding the decreased eNOS phosphorylation under elevated redox stress, the MCPIPincreased reactive oxygen species level can inhibit the PTEN-PI3K pathway, thereby attenuating Akt activity. This notion is supported by a deactivated Akt-eNOS pathway under longterm oxidative stress. 28 Alternatively, eNOS activity may be altered by reactive oxygen species-induced S-nitrosylation. 29 Our results imply that MCP-1 induction of MCPIP level in ECs under RA is proinflammatory, which is consistent with MCPIP induction of the JNK-p38-p53-PUMA pathway, tumor necrosis factor receptor, and tumor necrosis factor receptor-associated protein in cardiomyocytes and cardiomyoblasts. 10, 14, 31, 32 The proinflammatory role of MCPIP is further evidenced by its reduced expression in ECs and vessels from CIA mice administered with statins ( Figure 6 ). Statins exert their anti-inflammatory effect by inhibiting NF-κB-mediated transactivation. 33 The simvastatin inhibition of NF-κB binding to the MCPIP enhancer (in Figure 6E ), like the action of vascular cell adhesion molecule 1 and intracellular adhesion molecule 1, 34 reinforces the proinflammatory role of MCPIP in ECs. However, MCPIP may have a variety of biological effects depending on the tissue and pathophysiological condition. 32, 35 Containing an RNase-characteristic PIN-like domain, MCPIP can also act as an RNase to degrade its own mRNA and that of chemokines, such as IL-1, IL-6, and IL-12p40. 11 Furthermore, a feedback loop between NF-κB and MCPIP seems to exist; NF-κB transcriptionally activates MCPIP expression, and MCPIP can also decrease NF-κB activity. 25 When exerting these anti-inflammatory effects in ECs, MCPIP may regulate an endothelial network of inflammation or anti-inflammation.
If MCPIP is secreted from inflamed ECs to affect other cells in the cardiovascular system, circulating levels of MCPIP may be a clinical marker for cardiovascular events and poor prognosis of atherosclerosis. Because MCP-1 is involved in myocarditis, ischemia-reperfusion injury, cardiac remodeling, angiogenesis, and immunosuppression, 36 A and B , HUVECs were transiently transfected with pcDNA3 or MCPIP-pcDNA3 plasmid for 24 hours. C and D, EOMA cells were treated with 10% DBA/1j control or collagen-induced arthritis (CIA) mouse sera (described in Figure  2 ) for 24 hours. E and F, HUVECs were treated with 10% rheumatoid arthritis (RA) or OA sera (described in Figure 2 ) for 24 hours. In all groups, the transfected cells were treated with or without SOD (1.0×10 5 U/L) or vascular endothelial growth factor (VEGF) for 30 minutes before lysis. Western blot analysis with the indicated antibodies (A, C, and E) and reactive oxygen species (ROS) were monitored with an ROS-sensing fluorescent dye (B, D, and F). Data are mean±SD from 3 independent experiments. *P<0.05; **P<0.01 as compared with respective control group or basal level or as indicated. OA indicates osteoarthritis.
drugs for RA 37 but have multiple side effects, including high incidence of tuberculosis 38 and decreased anti-inflammation effects. 39 MCPIP antagonist may be an adjuvant agent for RA. These drugs, like statins, may benefit patients with vascular diseases manifested by dysfunctional endothelium. A to C, Collagen-induced arthritis (CIA) mice were fed simvastatin or were mock fed (n=8 in each group) for 9 weeks. Isolated aortic rings underwent endothelial-dependent (Ach) and endothelial-independent (SNP) vaso-relaxation assays (A and B) and pooled aortic extracts underwent Western blot analysis (C). A and B, A curve fit program in GraphPad was used to create the curves, and 2-way ANOVA was used to analyze the data. D, EOMA cells were pretreated with indicated concentrations (μmol/L) of simvastatin for 3 hours before the addition of recombinant mouse MCP-1 (12 nmol/L) for an additional 12 hours. Western blot analysis of protein level of MCPIP. GADPH was a normalization control. E, HUVECs were treated with recombinant human MCP-1 with or without simvastatin. Anti-p65 or IgG was used to immunoprecipitate isolated nuclear extracts. Quantitative PCR was then performed with the use of primers specific for the enhancer of the MCPIP (2791-2982). F, A model of rheumatoid arthritis (RA)-induced endothelial dysfunction. MCP-1 expression is elevated in the inflamed articulation during the pathogenesis of RA. The increased MCP-1 in circulation binds to chemokine (C-C motif) receptor 2 (CCR2) in ECs, leading to nuclear factor κB (NF-κB) transactivation of MCPIP. Redox stress is increased, which in turn inhibits endothelial-dependent Akt activity and impairs endothelial NO synthase (eNOS)-derived NO bioavailability. Such endothelial dysfunction is alleviated through statin inhibition of NF-κB binding to the enhancer region of the MCPIP promoter. Data are mean±SD from 3 independent experiments. *P<0.05; **P<0.01 as compared with respective control groups. ROS indicates reactive oxygen species.
